RGDXQ (Response Genetics) EBITDA Margin %: 0.00% (As of Dec. 2015)

What is Response Genetics EBITDA Margin %?

Response Genetics RGDXQ -98.00% EBITDA Margin % is 0.00% as of Dec. 2015.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Response Genetics's EBITDA for the three months ended in Dec. 2015 was $0.00 Mil. Response Genetics's Revenue for the three months ended in Dec. 2015 was $0.00 Mil. Therefore, Response Genetics's EBITDA margin for the quarter that ended in Dec. 2015 was 0.00%.

Response Genetics (OTCPK:RGDXQ) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Response Genetics EBITDA Margin % Related Terms

Response Genetics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Response Genetics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Response Genetics EBITDA Margin % Chart

Response Genetics Annual Data

Trend

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

EBITDA Margin %

Get a 7-Day Free Trial

-23.47

-38.43

-156.17

-173.37

-107.33

Response Genetics Quarterly Data
	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Dec15
EBITDA Margin %	Get a 7-Day Free Trial															-67.62	-71.22	341.24	-90.98	0.00

RGDXQ vs PSID, GBSN, ETAH: EBITDA Margin % Comparison

For the Diagnostics & Research subindustry, Response Genetics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Response Genetics EBITDA Margin % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Response Genetics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Response Genetics's EBITDA Margin % falls into.

Save Embed

Response Genetics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Response Genetics's EBITDA Margin % for the fiscal year that ended in Dec. 2015 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2015 )	/	Revenue (A: Dec. 2015 )
	=	-19.362	/	18.04
	=	-107.33 %

Response Genetics's EBITDA Margin % for the quarter that ended in Dec. 2015 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2015 )	/	Revenue (Q: Dec. 2015 )
	=	0	/	0
	=	%

Frequently Asked Questions Learn more about EBITDA Margin % →

What does a EBITDA Margin % of 0.00% mean?

Response Genetics (RGDXQ) has a EBITDA Margin % of 0.00% as of Dec. 2015. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Response Genetics and its competitors.

Is Response Genetics' EBITDA Margin % too high?

Response Genetics' current EBITDA Margin % is 0.00%.

How does Response Genetics' EBITDA Margin % compare to PSID and GBSN?

Response Genetics' EBITDA Margin % of 0.00% can be compared against companies in the Medical Diagnostics & Research industry. The industry median EBITDA Margin % is 5.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBITDA Margin % for a Medical Diagnostics & Research company?

The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.00, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBITDA Margin % mean?

A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Response Genetics and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Response Genetics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Response Genetics stock overvalued right now?

Response Genetics (RGDXQ) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBITDA Margin % calculated?

EBITDA Margin % is calculated from a company's financial statements. For Response Genetics (RGDXQ), the current EBITDA Margin % is 0.00% as of Dec. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Response Genetics Business Description

Industry Healthcare Medical Diagnostics & Research

Comparable Companies PSID GBSN ETAH IMEXF OXIS ABMC ATOS MEDD BTHCF MTST DIGP ROSG IDYLF BZYR TBIOD TEAR GNWSF LEDIF ROKA GENE

Address 201 Route 17 North, 2nd Floor, Rutherford, NJ, USA, 07070

Website http://www.responsegenetics.com

Response Genetics Inc develops and sells diagnostic tests. It provides molecular- and biomarker-based tests and services which enables physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment. The group generates revenue from providing Biopharma Services, Clinical Services, and Discovery Services, of which majority of the revenue is derived from providing Biopharma Services. Biopharma services provide companies with customized solutions for patient stratification and treatment selection through molecular- and biomarker-based testing services, customized assay development and trial design consultation. The firm operates in the US and internationally and generates prime revenue from the US.